Skip to main content
MTVA
NASDAQ Life Sciences

MetaVia 10-Q: $8.8M Cash Into 1Q 2027, $13.8M Nine-Month Loss, Going Concern Stands

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$1.4
Mkt Cap
$8.565M
52W Low
$0.966
52W High
$13.42
52W Position info
45% above low
Off High info
90% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

MTVA sits 45% above its 52-week low of $0.966.

Summary

MetaVia's Q3 10-Q confirms a $4.6M quarterly net loss and $8.8M of cash it says lasts into 1Q 2027, with a $13.8M nine-month loss, a $162.6M accumulated deficit and a repeated going-concern warning. The 2027 Phase 2 trials depend on raising more capital.


Key Events · Earnings and Guidance · MTVA

  • Q3 Loss and Cash Balance

    Net loss of $4.6M, or $0.69 per share, for the quarter ended September 30, 2026, on 6,679,250 weighted average shares. Cash and cash equivalents were $8.8M, down from $10.3M at December 31, 2025.

  • Nine-Month Burn Outpaces Prior Year

    Nine-month net loss was $13.8M versus $11.0M a year earlier, with net cash used in operations of $11.7M. R&D rose to $8.2M from $6.6M, driven by DA-1726 direct costs of $6.1M versus $4.1M.

  • Going Concern Repeated

    The filing states substantial doubt about the ability to continue as a going concern within one year, citing the $162.6M accumulated deficit and ongoing clinical spending. Management plans to fund through equity, debt, warrant exercises or partnerships.

  • Runway Ends Before 2027 Trials

    Cash is expected to last into 1Q 2027, while the 48-week Phase 2 in MetALD/ALD is targeted for 2H 2027 and the vanoglipel combination Phase 2a for 1H 2027; the filing states those programs are contingent on additional financing.


Analysis · MTVA · Life Sciences

The headline numbers were already out this morning, but the full 10-Q is what shows how thin the balance sheet is. Cash fell to $8.8M from $10.3M at December 31, 2025, while nine-month operating burn ran $11.7M — so the runway into 1Q 2027 depends on continued ATM sales and warrant exercises, not on operations. Management repeats the substantial-doubt going-concern language, and the 2027 Phase 2 programs in MetALD/ALD and the vanoglipel combination are contingent on raising more money. Existing holders also face a large overhang: 8.9M warrants outstanding against 6.7M shares, with 8.2M of those struck at $3.10 versus a $1.40 stock price, so they are unlikely to be exercised for cash soon.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MTVA was trading at $1.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.6M. The 52-week trading range was $0.97 to $13.42. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MTVA - Latest Insights

MTVA
Nov 18, 2026, 9:01 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.23
Real-time Price: $1.19 info
Change: -$0.045 (-4%) info
Market Cap: $7.99M info
MTVA
Nov 16, 2026, 9:01 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.27
Real-time Price: $1.19 info
Change: -$0.085 (-7%) info
Market Cap: $7.99M info
MTVA
Nov 13, 2026, 8:35 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.40
Real-time Price: $1.19 info
Change: -$0.215 (-15%) info
Market Cap: $7.99M info
MTVA
Nov 13, 2026, 8:31 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.40
Real-time Price: $1.19 info
Change: -$0.215 (-15%) info
Market Cap: $7.99M info
MTVA
Nov 12, 2026, 8:41 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.51
Real-time Price: $1.19 info
Change: -$0.325 (-22%) info
Market Cap: $7.99M info